BlossomHill Therapeutics files S-1 for IPO on Nasdaq under "BLSM"

BlossomHill Therapeutics filed a Form S-1 with the SEC on July 16, 2026, seeking an initial public offering of common stock. The company has applied to list its common stock on The Nasdaq Global Select Market under the symbol "BLSM," with the offering contingent on that approval.¹

BlossomHill describes itself as a clinical-stage biopharmaceutical company applying a chemistry-based approach to develop small molecule medicines for cancer treatment.¹ Its two clinical-stage programs are BH-30643, a non-covalent, macrocyclic OMNI-EGFR inhibitor for EGFR-mutant non-small cell lung cancer, and BH-30236, a CDC-like kinase inhibitor being evaluated in relapsed or refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes.¹ A preclinical candidate, BH-501284, targets activated KRAS.¹

BH-30643 is being tested in the SOLARA Phase 1/2 trial, enrolling at more than 40 sites across 10 countries.¹ The company plans to seek an end-of-Phase 1 meeting with the FDA in the fourth quarter of 2026 regarding a potential accelerated approval pathway, and expects to dose the first patient in a planned pivotal Phase 2 trial in the first quarter of 2027.¹ For BH-30236, the company expects to report updated safety and efficacy data in the first half of 2027.¹ BlossomHill plans to submit an IND for BH-501284 in the first quarter of 2027.¹

Financially, the company reported net losses of approximately $30.7 million in 2024 and $60.6 million in 2025, with net losses of $10.5 million and $21.0 million for the three months ended March 31, 2025 and 2026 respectively, and an accumulated deficit of approximately $156.0 million as of March 31, 2026.¹ Since inception, the company has raised over $257 million in capital from investors including Cormorant Asset Management, OrbiMed, Vivo Capital, and Janus Henderson Investors.¹